Key takeaways
- Pattern hair loss is follicle miniaturisation rather than hair falling out, which is why the window for intervention closes before baldness is visible.
- Susceptibility is inherited and lives in scalp androgen receptors; the hormone is uniform, the tissue response is not.
- Photograph the hairline and crown before starting, and start preservation alongside therapy rather than after loss appears.
This is the question men ask last, quietly, after everything else has been settled. It deserves a straight answer rather than reassurance. Testosterone therapy does not create male pattern baldness. In a man who was going to lose his hair, it can bring the timeline forward. Whether that applies to you is largely decided by genetics you already have, and it is knowable before you start.
What pattern hair loss actually is
Androgenetic alopecia is not hair falling out. It is hair getting smaller. Each follicle cycles through a growth phase, a brief transition and a resting phase, and in susceptible follicles the growth phase shortens with every cycle. The hair produced gets finer, shorter and lighter each time round — terminal hair becomes vellus hair, the near-invisible fuzz that covers most of the body — until the follicle stops producing anything worth seeing.
Two consequences follow. The process is gradual and largely silent — by the time thinning is obvious in the mirror, many follicles in that region have already been through several shortened cycles. And the window for intervention is defined by miniaturisation rather than by baldness: a miniaturised follicle can often be pushed back toward terminal hair, while one that has closed cannot.
The DHT mechanism
Testosterone is converted to dihydrotestosterone by the enzyme 5-alpha reductase, which is concentrated in scalp, prostate and skin. DHT binds the androgen receptor more tightly and for longer than testosterone does, making it the more potent androgen at the tissue level. In genetically susceptible men, DHT binding at scalp follicles is what drives the cycle-shortening described above (Russell & Wilson, Annu Rev Biochem 1994).
Testosterone therapy raises serum testosterone, and DHT rises broadly in proportion because the enzyme has more substrate to work on (Swerdloff et al., J Clin Endocrinol Metab 2000). More DHT means more androgen signal at follicles that are already primed to respond badly to it.
The part that gets missed: susceptibility lives in the follicle, not in the hormone. Two men with identical DHT levels can have completely different outcomes, because what differs is androgen receptor density and sensitivity in scalp tissue, which is inherited. It is why the same hormone thickens beard hair and thins scalp hair in the same person at the same time.
Who is actually at risk
Genetic susceptibility is the prerequisite, and it is strongly heritable — genome-wide work has now mapped hundreds of independent risk loci (Heilmann-Heimbach et al., Nat Commun 2017). That polygenic architecture is also why the old shorthand about inheriting it from your mother's father is unreliable; the risk comes from both sides.
- Family history of pattern baldness: at risk for acceleration
- Already showing pattern thinning: at high risk of faster progression
- No family history, no current thinning: low risk
- Asian or African ancestry with full hair: generally lower genetic susceptibility
The practical triage is three questions, asked before the first injection. Did your father, uncles or older brothers lose hair, and at what age? Is your hairline where it was at twenty-five, checked against a photograph rather than memory? And is there visible thinning at the crown — the region men cannot see without a second mirror and therefore rarely check? If all three answers are reassuring, this is a low-priority concern. If two or three point the other way, plan for it rather than hope.
When it would show up, and what it looks like
If therapy is going to accelerate hair loss, the change is usually noticeable within three to nine months, typically as increased shedding, thinning at the temples or crown, or visible miniaturisation of the hairs that remain. That window is not arbitrary — it reflects the time it takes for follicles to complete a cycle under a changed hormonal signal.
Change earlier than that is usually something else. Starting therapy tends to coincide with upheaval — new routine, new training, sometimes significant weight change — and telogen effluvium, a diffuse shed triggered by physiological stress, is easily mistaken for pattern loss. It is diffuse rather than patterned, it resolves, and it does not follow the temple-and-crown geography.
Change appearing later and following that geography is the genetic acceleration pattern. Photograph the hairline and crown before starting, in the same light — memory is a poor instrument for gradual change, and this is the cheapest thing you can do to make the question answerable later.
Prevention strategies
| Approach | How it works | Notes |
|---|---|---|
| Topical minoxidil | Prolongs the growth phase, improves follicular blood flow | Over the counter, well tolerated, mild benefit. Expect an initial shed |
| Topical finasteride | Local 5-AR inhibition at the scalp | Lower systemic exposure than oral; less long-term data |
| Oral finasteride | Systemic 5-AR inhibition, mainly type 2 | Most established; a minority of men report sexual or mood side effects (see the 5-alpha reductase article) |
| Oral dutasteride | Inhibits both type 1 and type 2 5-AR | Strongest hair preservation; same side effect profile, longer half-life |
| Microneedling | Wound-healing signalling, improves topical absorption | Adjunct, not primary |
| Lower testosterone dose | Less substrate for conversion | Modest effect; trades away therapeutic benefit for a small change |
Two things that do not belong on that list. Blocking aromatase does nothing for hair — that pathway makes estradiol, not DHT, and suppressing it carries real costs elsewhere, as estradiol management on testosterone therapy sets out. And ketoconazole shampoo, saw palmetto and the rest of the supplement shelf have far weaker evidence than the interventions above; they are not harmful, they are simply not the thing doing the work.
Making the decision
The trade-off is worth naming rather than glossing. 5-alpha reductase inhibition is the effective intervention, and DHT is not only a scalp hormone — it contributes to libido and erectile function, and a minority of men on these drugs report persistent complaints in exactly that domain. How common and how durable that is remains disputed. The reasonable position: the risk is small, real and not zero, and a man told it is zero has been sold something rather than informed.
Given that, most men fall into one of three positions. Low genetic risk: proceed, photograph, revisit if anything changes. High risk and hair matters: start a preservation strategy at the same time as therapy rather than waiting for loss to appear, because the intervention protects what is present far better than it recovers what has gone. High risk and hair does not matter: proceed, and stop relitigating it.
If hair loss has already started
Earlier intervention produces better results, and the reason is mechanistic rather than motivational. Follicles in early-to-mid miniaturisation can be pushed back toward terminal growth; follicles that have fully terminated cannot be brought back by any drug. 5-alpha reductase inhibition has randomised evidence for slowing progression and partially reversing pattern hair loss (Kaufman et al., J Am Acad Dermatol 1998).
Expect slow movement in both directions. Preservation shows up as the absence of further loss, which is hard to perceive without baseline photographs. Regrowth, where it happens, takes many months and is usually partial. Anyone promising faster or more complete is describing a transplant, which is a different conversation.
The principle: testosterone therapy does not create new genetic susceptibility. It accelerates what genetics already wrote. For susceptible men, running hair preservation in parallel keeps the benefits of treatment without paying for them in hair — and starting it alongside therapy works considerably better than starting it after the mirror makes the case.
Bottom line
The headline that testosterone causes baldness is too simple to be useful. Therapy raises DHT, DHT drives miniaturisation in follicles that are genetically primed for it, and men without that priming are largely unaffected. Check the family history and photograph the hairline before you start. If you are susceptible and you care, begin a preservation strategy at the same time rather than reactively, and accept the small but genuine trade-off that comes with 5-alpha reductase inhibition. If you are not susceptible, this is not the concern that should decide anything — the symptom checklist and a properly interpreted panel are the things worth your attention, and the 60-second assessment puts both in front of a physician.
Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.
